Nektar falls on TNBC data for doublet, but considering moving ahead with a triple combo

Despite shedding over $200 million from its market cap Thursday after reporting response data from the triple-negative breast cancer cohort of its bempegaldesleukin/Opdivo nivolumab combination trial, Nektar is looking ahead to the next set of trials for the combo.

In the Phase I/II PIVOT-02 trial,

Read the full 454 word article

How to gain access

Continue reading with a
two-week free trial.